Human Longevity announced a multi-year agreement with Genentech to conduct whole genome sequencing of tens of thousands of de-identified samples Read the full story
Human Longevity announced a multi-year agreement with Genentech to conduct whole genome sequencing of tens of thousands of de-identified samples Read the full story
NewLink Genetics has inked a pharma deal potentially worth $1 billion with Genentech for the development of NLG919, NewLink's IDO pathway inhibitor. Read the full story
Genentech has entered into biotech deals with Arrayit to purchase a drug discovery tool for $138,000. Read the full story
Biologics pharma deals Genentech to be part of a limited group of specialty pharmacies authorized to distribute Tarceva. Read the full story
Immunocore has entered into pharma deals involving a collaborative R&D and licensing agreement with Genentech for the discovery and development of multiple novel cancer targets using Immunocore’s ImmTAC technology. Read the full story
Genentech is a top biotech company, subsidiary of Swiss pharma giant Roche, and active in partnering, licensing in, biotech healthcare Read the full story
Roche is a top pharma company active in partnering, licensing and M&A in pharmaceuticals and biotechology Read the full story
Roche announced over 375 partnering / licensing deals since 2005, with over 24 deals in 2012 alone, whilst Genentech announced over 98 partnering / licensing deals since 2005 Read the full story
Roche, a top pharmaceutical/biotechnology company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story